Patrick Therasse News Today

/PRNewswire/ -- Servier will showcase new data from its vorasidenib clinical development program in a plenary townhall at the 28th Annual Meeting of the...

One of the trial results that caused a stir in Chicago has raised hopes for a new weapon against lung cancer, the deadliest of all cancers.

Dailytimes.com.pk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailytimes.com.pk Daily Mail and Mail on Sunday newspapers.

New advances in fight against a range of cancers have been revealed at annual meeting of American Society of Clinical Oncology, which wraps up in Chicago on Tuesday

New advances in the fight against a range of cancers have been revealed at the annual meeting of the American Society of Clinical Oncology (ASCO), which wraps up in Chicago on Tuesday. Here are some of the announcements that have most excited experts. - Lung cancer - One of the trial results that ca ..

New advances in the fight against a range of cancers have been revealed at the annual meeting of the American Society of Clinical Oncology (ASCO), which wraps up in Chicago on Tuesday.

A roundup of some of the most promising announcements at a meeting of the American Society of Clinical Oncology.

Paris - New advances in the fight against a range of cancers have been revealed at the annual meeting of the American Society of Clinical Oncology (ASCO

Servier, a global independent pharmaceutical group, announced today that the primary objective (progression free survival) of the Phase III SOLSTICE trial has not been met. SOLSTICE was designed to evaluate

(2) Servier announced today updated results from the exploratory phase II TASCO1 study evaluating LONSURF (trifluridine/tipiracil) bevacizumab and capecitabine bevacizumab (C-B) in a first-line setting for patients with unresectable metastatic colorectal cancer (mCRC) who are non-eligible for intensive therapy. 1 The data were announced today during an oral presentation at the 2021 ASCO Gastrointestinal Cancers Symposium (ASCO-GI). Patients with mCRC who are not eligible for chemotherapy face ...